Most ICBs in England do not have effective referral pathways for diagnosing and managing liver disease, an analysis has shown ...

Researchers from Hokkaido University of Science presented data from a study that aimed to assess the impact of reverse erythroblastosis virus (REV)-ERBα agonist, SR-9009, on renal fibrosis.

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Fortier hopes the discovery that this pathway reverses fibrosis leads to exploration of additional brakes on fibrosis. "So much work on fibrosis has focused on how we can prevent it, but when a ...

They are key to the initiation and resolution of various types of lung injuries, but also are involved in pathways that lead to lung scarring (fibrosis). It is currently unclear what mechanisms ...

They are key to the initiation and resolution of various types of lung injuries, but also are involved in pathways that lead to lung scarring (fibrosis). It is currently unclear what mechanisms ...

There are few effective treatments for intestinal fibrosis because researchers have ... disrupts the macrophages and activates the HIF-1α pathway. Pro-fibrotic genes are then expressed in both ...

Now, however, the challenge is to prove that fibrosis can be reversed by a direct attack on the pathways of fibrogenesis and matrix degradation, instead of therapy directed only to the primary ...

The transcription factor sex-determining region Y-related high-mobility group-box gene 9 (SOX9) plays a critical role in ...

IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced its second FDA authorization, securing 510(k) cl ...